HSP27 AS A MOLECULAR TARGET FOR RADIATION THERAPY

来源 :第三届亚洲辐射研究大会 | 被引量 : 0次 | 上传用户:wlq8201
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Heat shock protein 27 (HSP27), which is highly expressed in various cancer tissues,induced resistance to cell death against various stimuli.
其他文献
To study the radiation effect of cosmic heavy ions of low fluxes in electronics and living samples, a focusing heavy ion microbeam facility, for ions with energies of from several MeV/u up to 100MeV/u
会议
With great advances achieved in the knowledge and utilizations of ionizing radiation in medicine, industry and human heath, further problems also keep emerging concerning the deeper mechanism of biolo
会议
The development of ASIPP micro-beam facility in our laboratory was firstly reviewed.We then introduced its structure, radiation parameters, real-time detection of biological effects and experimental d
DNA Ligase IV, one the most critical component of nonhomologous DNA end joining (NHEJ), is responsible for the final sealing of DNA double-strand breaks (DSBs).
会议
H2AX is an important factor for chromatin remodeling to facilitate accumulation of DNA damage-related proteins at DNA double-strand break (DSB) sites.
The Nobel Prize 2011 went to Jules Hoffman and Bruce Beutler for their discoveries of Toll-like receptors (TLRs), while Albert Lasker Award for Basic Medical Research 2008 honored the discovery of mic
DNA double-strand breaks (DSBs) are considered most deleterious among radiation-induced DNA damages.Eukaryotic cells repair DSBs mainly through two pathways: non-homologous end joining (NHEJ) and homo
会议
Esophageal cancer is still one of the deadliest cancers today with the average 5-years survival rate less than 25%.Although the diagnosis and the treatment options have been improved during the past d
会议
Based on the results of several randomized phase Ⅲ clinical studies and meta-analyses, concurrent chemoradiotherapy (CCRT) using weekly cisplatin or the combination of cisplatin and 5-FU has become th
Pancreatic cancer is one of the leading causes of cancer death worldwide.The prognosis of patients with this disease remains extremely poor, with a 5-year survival rate after diagnosis of less than 5%